MinervaX announces that it today data have been received from the primary 3-month time point clinical endpoint of the Phase I Part B. The data supports dose-selection made based on Part A. The data further supports the vaccine is highly immunogenic already 14 days after the first dose, and that the antibodies are functionally active in killing Group B Streptococcus and preventing host-invasion.
Recent Posts
- MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults 27/06/2023
- MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults 17/04/2023
- MVX0006 Phase I 03/04/2023
- MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine 05/01/2023
- MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus 15/12/2022